BridgeMD
Impact of Glucagon on Physical Capacity and Metabolism
EU CTIS ID: 2025-521835-35-00
What this study is testing
To investigate the metabolic effects and impact on physical performance as measured by VO2max of continuously subcutaneously administered glucagon in HFpEF patients with and without concomitant MASLD.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 18 - 80 years and able to understand the requirements of the study and willing to provide signed informed consent for voluntary participation in the study
- Patients with clinically confirmed heart failure with preserved ejection fraction (HFpEF) by: a) Symptoms and signs of heart failure b) Left ventricular ejection fraction ≥ 45% c) Objective signs of structural and/or functional cardiac dysfunction consistent with the presence of left ventricular diastolic dysfunction/elevated left ventricular filling pressures, including elevated serum natriuretic peptides
- Metabolic associated steatotic liver disease (MASLD) without higher-level fibrosis (F3) confirmed by o Transient elastography Elasticity (E) ≥ 8 - And At least stetosis I-II (CAP ≥248 - ≤ 280 dB/m) o Presence of at least 1 cardiometabolic criterion BMI > 25 kg/m2 Fasting BG > 100 mg/dl or 2h postprandial >140mg/dl or already diagnosed type 2 diabetes mellitus RR >130/85mmHg or under antihypertensive therapy Fasting triglycerides > 150 mg/dl or under therapy HDL < 40 mg/dl (m) and < 50 mg/dl (w)
You likely can't join if
- History of acute coronary syndrome or percutaneous coronary intervention/bypass surgery or cerebrovascular event (e.g. stroke) within the last 6 months
- Existing contraindications for carrying out a cardiopulmonary performance test
- Pregnancy
- Inability to give informed consent/ inability to make independent decisions
- Substance abuse (illegal drugs)
- Employment relationship with the sponsor or the conducting clinic
See the full eligibility criteria
- Age between 18 - 80 years and able to understand the requirements of the study and willing to provide signed informed consent for voluntary participation in the study
- Patients with clinically confirmed heart failure with preserved ejection fraction (HFpEF) by: a) Symptoms and signs of heart failure b) Left ventricular ejection fraction ≥ 45% c) Objective signs of structural and/or functional cardiac dysfunction consistent with the presence of left ventricular diastolic dysfunction/elevated left ventricular filling pressures, including elevated serum natriuretic peptides
- Metabolic associated steatotic liver disease (MASLD) without higher-level fibrosis (F3) confirmed by o Transient elastography Elasticity (E) ≥ 8 - And At least stetosis I-II (CAP ≥248 - ≤ 280 dB/m) o Presence of at least 1 cardiometabolic criterion BMI > 25 kg/m2 Fasting BG > 100 mg/dl or 2h postprandial >140mg/dl or already diagnosed type 2 diabetes mellitus RR >130/85mmHg or under antihypertensive therapy Fasting triglycerides > 150 mg/dl or under therapy HDL < 40 mg/dl (m) and < 50 mg/dl (w)
- History of acute coronary syndrome or percutaneous coronary intervention/bypass surgery or cerebrovascular event (e.g. stroke) within the last 6 months
- Existing contraindications for carrying out a cardiopulmonary performance test
- Pregnancy
- Inability to give informed consent/ inability to make independent decisions
- Substance abuse (illegal drugs)
- Employment relationship with the sponsor or the conducting clinic
- Known allergies or intolerances in connection with study medication
- Simultaneous participation in another clinical trial or intervention study or participation in a clinical trial or intervention study within the last 3 months
- Severe or high-grade heart valve stenosis and/or insufficiency
- Left ventricular ejection fraction < 45%
- Known significant MASLD with advanced fibrosis (grade III - IV) and/or liver cirrhosis and/or alcohol-induced liver disease
- Known severely impaired renal function (eGFR <30ml/min according to CKD-EPI formula)
- Known active malignant disease and/or known active underlying inflammatory or infectious disease
- Type I diabetes mellitus or insulin-dependent type II diabetes mellitus
- Obesity per magna (BMI >40 kg/m2)
- Physical/physical limitations that impair mobility or performance o E.g. underlying neuromuscular diseases, anaemia (anaemia < 12 g/dl), acute and/or chronic orthopaedic diseases that restrict physical mobility/performance, congenital heart defects
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.